Healthcare Costs of Treating Privately Insured Patients with Acute Myeloid Leukemia in the United States from 2004 to 2014: A Generalized Additive Modeling Approach.

PharmacoEconomics
Lih-Wen MauDavid J Vanness

Abstract

The primary objective of this study was to predict healthcare cost trajectories for patients with newly diagnosed acute myeloid leukemia (AML) receiving allogeneic hematopoietic cell transplantation (alloHCT), as a function of days since chemotherapy initiation, days relative to alloHCT, and days before death or last date of insurance eligibility (LDE). An exploratory objective examined patients with AML receiving chemotherapy only. We used Optum's de-identified Clinformatics® Data Mart Database to construct cumulative cost trajectories from chemotherapy initiation to death or LDE (through 31 December 2014) for US patients aged 20-74 years diagnosed between 1 March 2004 and 31 December 2013 (n = 187 alloHCT; n = 253 chemotherapy only). We used generalized additive modeling (GAM) to predict expected trajectories and bootstrapped confidence intervals (CIs) at user-specified intervals conditional on dates of alloHCT and death or LDE relative to chemotherapy initiation. Expected costs (in 2017 values) for a hypothetical patient receiving alloHCT 60 days after chemotherapy initiation and followed for 5 years were $US572,000 (95% CI 517,000-633,000); $US119,000 (95% CI 51,000-192,000); $US102,000 (95% CI 0-285,000); $US79,000 (95% CI...Continue Reading

References

Oct 5, 1988·Journal of the National Cancer Institute·F E HarrellB G Pollock
Sep 1, 1995·Statistical Methods in Medical Research·T Hastie, R Tibshirani
Dec 26, 2001·Journal of Clinical Epidemiology·T H Hauser, K K Ho
Jul 27, 2002·American Journal of Epidemiology·Francesca DominiciJonathan M Samet
Aug 21, 2002·Medical Care·Martin L BrownRuth Etzioni
Mar 10, 2006·Statistics in Medicine·Lei LiuJohn D Kalbfleisch
Jun 13, 2006·International Journal of Health Geographics·Thomas WebsterAnn Aschengrau
May 1, 2008·Journal of the National Cancer Institute·K Robin YabroffMartin L Brown
Aug 9, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Craig C EarleJohn Z Ayanian
Apr 14, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Navneet S MajhailDaniel J Weisdorf
Jun 19, 2009·Medical Care·William E Barlow
Jan 14, 2011·Journal of the National Cancer Institute·Angela B MariottoMartin L Brown
Mar 10, 2011·American Journal of Epidemiology·Michele Jonsson FunkMarie Davidian
May 10, 2011·BMC Medical Research Methodology·Jeroen P Jansen
Apr 10, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jaime M PreusslerNavneet S Majhail
May 18, 2012·Health Services & Outcomes Research Methodology·Claude Messan SetodjiEmmett Keeler
Jun 16, 2012·Blood·Nandita KheraStephanie J Lee
Oct 17, 2012·Leukemia Research·Annemieke LeunisCarin A Uyl-de Groot
Nov 8, 2012·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Eleanor M PullenayegumAaron Childs
Jan 17, 2013·Circulation. Cardiovascular Quality and Outcomes·Briget da GracaDavid Nicewander
Apr 20, 2013·Journal of Oncology Practice·Benjamin ChastekApril H Teitelbaum
Jun 14, 2013·Computational and Mathematical Methods in Medicine·Masaaki Tsujitani, Yusuke Tanaka
Sep 11, 2013·JAMA Internal Medicine·Thanh N HuynhNeil S Wenger
Sep 18, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gery P GuyKatherine S Virgo
Apr 26, 2016·Leukemia Research·A L Van de VeldeZ N Berneman
May 18, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jaime M PreusslerDavid J Vanness
Oct 18, 2016·Journal of Medical Economics·Thomas BramleyAnthony Masaquel
Oct 5, 2016·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Claire WilliamsAndrew H Briggs
Mar 7, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jaime M PreusslerDavid J Vanness
Jul 9, 2017·Journal of the National Comprehensive Cancer Network : JNCCN·Margaret R O'DonnellNdiya Ogba
Jul 26, 2017·Research Synthesis Methods·Suzanne C Freeman, James R Carpenter
Jan 1, 2018·Journal of the American Statistical Association·Liang LiYu Shen
May 6, 2019·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Jenna M RepsPatrick B Ryan
Aug 15, 2019·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Joseph F Levy, Marjorie A Rosenberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

© 2021 Meta ULC. All rights reserved